Armata Pharmaceuticals, Inc. (ARMP) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US04216R1023
Armata Pharmaceuticals, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Operating income | -36.63 m USD |
| EBIT | -173.80 m USD |
| Net income | -173.80 m USD |
| Diluted EPS – continuing operations | -4.80 USD |
Full history since 1993, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Armata Pharmaceuticals, Inc.
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA03 for Pseudomonas aeruginosa . The company is based in Los Angeles, California. Armata Pharmaceuticals, Inc. is a subsidiary of Innoviva, Inc.
More stocks
- Bonny Worldwide Ltd (8467.TW)
- N. Varveris-Moda Bagno S.A (MODA.AT)
- TDG Gold Corp (TDG.V)
- NEIGHBORHOOD INTELLIGENCE, INC. (NXH)
- Ion Electronic Materials Co., Ltd. (6959.TWO)
- Grupo Ortiz Properties Socimi (YGOP.MC)
- Akebia Therapeutics, Inc. (AKBA)
- Coraza Integrated Technology Bhd (0240.KL)
- Niko Semiconductor Co Ltd (3317.TWO)
- Best Precision Industrial Co., Ltd. (6859.TWO)
- AJ Networks Co Ltd (095570.KS)
- Angel Oak Mortgage REIT, Inc. (AOMR)
Not investment advice. All data without warranty, price as of 05.11.2026. Details in the risk notice.